Inspira Technologies Oxy B.H.N. Ltd. (IINN)
NASDAQ: IINN · Real-Time Price · USD
0.844
-0.005 (-0.59%)
At close: Feb 4, 2025, 4:00 PM
0.857
+0.013 (1.49%)
After-hours: Feb 4, 2025, 7:40 PM EST

Company Description

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure.

Its lead product is the INSPIRA augmented respiration technology (Gen 2) device, a life support designed to provide Adaptive Blood Oxygenation that to elevate and stabilize declining oxygen saturation levels.

The company has a strategic collaboration with Westchester Medical Center to advance critical patient care with the deployment of Inspira's proprietary INSPIRA ART100 systems.

The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N.

Ltd. in July 2020. Inspira Technologies Oxy B.H.N.

Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.

Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. logo
Country Israel
Founded 2018
IPO Date Jul 14, 2021
Industry Medical Devices
Sector Healthcare
Employees 42
CEO Dagi Ben-Noon

Contact Details

Address:
2 Ha-Tidhar Street
Ra'anana, 4366504
Israel
Phone 972 4 6230333
Website inspira-technologies.com

Stock Details

Ticker Symbol IINN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.51
CIK Code 0001837493
CUSIP Number M53637100
ISIN Number IL0011715781
SIC Code 3841

Key Executives

Name Position
Dagi Ben-Noon Chief Executive Officer
Yafit Tehila Chief Financial Officer
Avi Shabtai Chief Operating Officer

Latest SEC Filings

Date Type Title
Jan 30, 2025 424B4 Prospectus
Jan 27, 2025 6-K Report of foreign issuer
Jan 23, 2025 EFFECT Notice of Effectiveness
Jan 21, 2025 6-K Report of foreign issuer
Jan 17, 2025 6-K Report of foreign issuer
Jan 16, 2025 F-3 Filing
Jan 14, 2025 6-K Report of foreign issuer
Jan 10, 2025 6-K Report of foreign issuer
Jan 7, 2025 D Notice of Exempt Offering of Securities
Jan 7, 2025 6-K Report of foreign issuer